Generic Drug Supply Chain Challenges: Overseas Reliance and Strategies to Save $450 Billion

Generic drugs contribute significantly to healthcare cost savings, but also face supply chain challenges, according to recent findings. Optimizing the supply chain, building relationships, implementing quality control, investing in digital transformation, and fostering collaboration are key strategies. Generic drugs have the potential to save the U.S. healthcare system $450 billion annually if they reach 100% market share. However, the supply chain relies heavily on overseas manufacturing, with 90% of generic drugs manufactured abroad and 70% originating from India and China. Shortages affect one in five generic drugs, leading to increased costs and reduced patient access. To overcome these challenges, the industry is exploring optimization, building strong relationships with manufacturers and distributors, implementing quality control measures, investing in digital transformation and data analytics, and fostering collaboration among stakeholders.

Newsflash | Powered by GeneOnline AI
Date: April 9, 2025

Related posts:

DrugPatentWatch: Strong Product Pipeline and Patent Portfolio Drive Pharmaceutical Company Valuation US Generic Drug Prices Average 10 Times Higher Than Other Developed Nations, Study Finds Navigating Drug Combination Patents: FDA’s Orange Book a Key Resource Analysis: Pharmaceutical Firms Need Proactive Patent Strategies to Navigate Lifecycle, Milestones, and Regulatory Changes

Author

Mark Chiang